On August 1, 2012, New York-based Bristol-Myers Squibb Company reported that it discontinued development of the experimental hepatitis C drug BMS-986094 (formerly INX-189), after the death of a patient from heart failure.
Bayer HealthCare is in the process of communicating with patients, through letters and e-mails to pharmacies and distributors, on the importance of the label information for filtering both Kogenate® FS and Kogenate® FS with BIO-SET.
REGENX BioSciences, LLC recently announced that it has entered into an agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of therapies to treat hemophilia A.
In April, Inspiration Biopharmaceuticals, Inc., announced that it had submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of IB1001, its recombinant factor IX (rFIX) product for the treatment and prevention of bleeding in individuals with hemophilia B.
Last month, Vertex Pharmaceuticals announced the interim results from an ongoing Phase II study to evaluate the safety and tolerability of the company’s protease inhibitor (PI) therapy Incivek™ (telaprevir), when taken with the standard combination therapy of pegylated-interferon and ribavirin.
CSL Behring has announced that the first patient has been screened for an open-label, multicenter Phase I/III clinical study into a single chain recombinant factor VIII (rFVIII) product called “rFVIII-SingleChain.”